Leschly stays as SKB denies merger moves
Wednesday 21 October 1998
Mr Leschly used the publication of the company's third-quarter results, which beat market expectations, to dismiss reports of his impending retirement as "simply not true". He said: "I have no plans for retirement. This is just speculation."
Mr Leschly, 58, said he intended to remain at the helm of the UK's second- largest drugs group until September 2000 when he will reach 60, the company's retirement age. He added that any other decision, including a move to non-executive chairman, would have to be taken by the board.
Recent speculation that Mr Leschly would leave SKB triggered rumours that the company might reopen merger talks with Glaxo Wellcome. The planned pounds 13bn tie-up between the UK's leading drugs groups foundered in February after a clash of personalities between Mr Leschly and Sir Richard Sykes, the Glaxo chairman.
Yesterday Mr Leschly said the deal with Glaxo was "behind us. The prospects for SKB as an independent company are better than if we have a merger that is not done properly".
The SKB chief executive also ruled out reopening talks with AHP, which were abandoned earlier this year, after last week's collapse of the US group's merger with the life sciences group Monsanto.
His comments came as SKB posted a 10 per cent rise in underlying profits in the third quarter to pounds 415m, in line with its double-digit growth target. The figures sent the shares 27.5p higher to 686.5p.
SKB revealed that a possible new blockbuster, the diabetes drug Avandia, could be launched into the market in just over a year's time. SKB is to seek US regulatory approval for the treatment, which could reap annual sales of up to $1bn (pounds 590m), by the end of the year.
The company said that its laboratory near Cork, Ireland, would be expanded, creating 320 jobs in the next five years.
Investment column, page 20
filmNymphomaniac is more Carl Dreyer than sexploitation of Russ Meyer
elephant appealThe first 23 lots in our charity auction have now gone. But there are 22 more still up for grabs
scienceScientists find the answer to a question that even puzzled Darwin
arts + entsThe 'Friends' actor on his new role as campaigner on addiction issues
Geoffrey Macnab: The Wolf of Wall Street's account of white-collar excess is A Rake’s Progress on steroids
scienceThe new development in bio-printing technology could be used in the future to restore lost vision - though years of research still await
architectureThe design collective which has stuck two fingers up at the modernists will call it quits at Venice
... But if you’re one of those poor souls offended by Jennifer Lopez’s choice of leotard, Grace Dent want you to get a bloody grip
Sun will 'flip upside down' within weeks, says Nasa
Colin Farrell reveals ‘affair’ with Elizabeth Taylor: 'She was my last romantic relationship'
Children evacuated from swimming pool after prosthetic leg mistaken for paedophile
India-US row over escalates over arrest of diplomat Devyani Khobragade in New York
Peter O'Toole: Tales of the late film icon
- 1 Facebook 'self-censorship': study records when you don't post to find more ways to share
- 2 Sun will 'flip upside down' within weeks, says Nasa
- 3 British prisoner Dr Abbas Khan found dead in Syrian jail days before he was due to be handed over to MP George Galloway
- 4 Vitamin pills are a waste of money, offer no health benefits and could be harmful - study
- 5 Children evacuated from swimming pool after prosthetic leg mistaken for paedophile
- < Previous
- Next >
iJobs Money & Business
£50000 - £75000 per annum + benefits + bonus: Harrington Starr: Implementation...
£50000 - £65000 per annum + benefits + bonus: Harrington Starr: Project Manage...
Negotiable: Harrington Starr: My client deliver into the Investment Managemen...
£25000 - £35000 per annum + Bonus and Benefits: Harrington Starr: Harrington S...